Maravai LifeSciences/$MRVI
Maravai stock falls after Q2 results showed 8.5% revenue growth, a $21.6M net loss and despite raising full-year EBITDA guidance to $33M–$35M.
16 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Maravai LifeSciences
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
Ticker
$MRVI
Sector
Primary listing
Employees
416
Headquarters
Website
MRVI Metrics
BasicAdvanced
$919m
-
-$0.53
-
-
Price and volume
Market cap
$919m
52-week high
$7.44
52-week low
$2.03
Average daily volume
2.8m
Financial strength
Total debt to equity
85.356
Interest coverage (TTM)
-2.82%
Profitability
EBITDA (TTM)
-19.103
Gross margin (TTM)
35.71%
Net profit margin (TTM)
-37.07%
Operating margin (TTM)
-32.32%
Effective tax rate (TTM)
0.30%
Revenue per employee (TTM)
$500,000
Management effectiveness
Valuation
Price to revenue (TTM)
4.358
Price to book
4.34
Price to tangible book (TTM)
-14.64
Growth
Revenue change (TTM)
-5.03%
Earnings per share change (TTM)
-60.43%
3-year revenue growth (CAGR)
-27.33%
3-year earnings per share growth (CAGR)
-2.36%
What the Analysts think about MRVI
Analyst ratings (Buy, Hold, Sell) for Maravai LifeSciences stock.
MRVI Financial Performance
Revenues and expenses
MRVI Earnings Performance
Company profitability
MRVI News
AllArticlesVideos
Maravai LifeSciences Q2 Earnings Call Highlights
MarketBeat·1 day ago
TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology
Business Wire·3 weeks ago
TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.